Global HER2 - Negative Breast Cancer Market to Reach US$21.5 Billion by 2030

The global market for HER2 - Negative Breast Cancer estimated at US$14.4 Billion in the year 2024, is expected to reach US$21.5 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Radiation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$8.9 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.9 Billion While China is Forecast to Grow at 10.9% CAGR

The HER2 - Negative Breast Cancer market in the U.S. is estimated at US$3.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global HER2 - Negative Breast Cancer Market - Key Trends and Drivers Summarized

HER2-negative breast cancer refers to a subtype of breast cancer that tests negative for human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells. Approximately 80% of all breast cancers are HER2-negative, which means they do not overexpress the HER2 protein. These cancers can be further categorized based on the presence or absence of hormone receptors (estrogen and progesterone receptors). Hormone receptor-positive HER2-negative breast cancers, which account for a significant proportion of cases, tend to respond well to hormone therapies that target estrogen or progesterone receptors. On the other hand, triple-negative breast cancer (TNBC), which is both HER2-negative and lacks hormone receptors, is often more aggressive and difficult to treat, as it does not respond to hormonal or HER2-targeted therapies.

The treatment landscape for HER2-negative breast cancer is diverse and continues to evolve with ongoing research and clinical advancements. For hormone receptor-positive HER2-negative breast cancers, endocrine therapies such as tamoxifen, aromatase inhibitors, and CDK4/6 inhibitors are commonly used to block the effects of estrogen and slow cancer growth. Chemotherapy remains a cornerstone of treatment for both hormone receptor-positive and triple-negative breast cancers, especially in advanced stages or metastatic disease. In recent years, immunotherapy and targeted therapies have emerged as promising options for triple-negative breast cancer. Drugs like pembrolizumab, an immune checkpoint inhibitor, and PARP inhibitors such as olaparib and talazoparib have shown efficacy in improving outcomes for patients with specific genetic profiles or those who have failed standard treatments. Additionally, the integration of genomic profiling in clinical practice allows for more personalized treatment approaches, tailoring therapies to the unique genetic makeup of each patient`s cancer.

The growth in the HER2-negative breast cancer therapeutics market is driven by several factors, including advancements in research and development that have led to new treatment modalities and improved patient outcomes. The increasing prevalence of breast cancer globally, coupled with heightened awareness and early detection efforts, has expanded the patient pool eligible for these therapies. Technological advancements in diagnostic tools and genetic testing enable more precise identification of cancer subtypes and more tailored treatment plans. Additionally, the shift towards personalized medicine and the development of novel drugs targeting specific pathways involved in cancer progression are significant drivers of market growth. Regulatory support and expedited approval processes for breakthrough therapies further facilitate the introduction of innovative treatments. The growing investment in oncology research, coupled with collaborations between pharmaceutical companies and research institutions, continues to fuel the pipeline of potential new therapies. These factors collectively ensure a robust and dynamic market for HER2-negative breast cancer therapeutics, providing hope for better management and improved survival rates for patients worldwide.